Melissa A. Babcook
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
36
Citations
679
Est. group size
~1
Recurring co-author estimate
Active years
16
Publishing since 2011
Melissa A. Babcook's publication record spans two distinct areas: early work on molecular pathways in prostate cancer (such as AMPK phosphorylation and metabolic drug combinations linked to cancer progression and treatment resistance), and more recent clinical research on complications and outcomes of cellular immunotherapies (CAR T-cell therapy) for blood cancers, including neurological side effects and treatment strategies after therapy failure. This body of work suggests a research trajectory that has shifted from basic cancer cell biology toward clinical and outcomes-focused studies in cancer immunotherapy.
Publication output was minimal or absent for several years in the middle of the decade, then increased noticeably from 2022 to 2023 before tapering off slightly through 2024-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Intrathecal Therapy for Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): An Updated Multicenter Analysis of Outcomes and Safety
Transplantation and Cellular Therapy · 2026
- Intrathecal chemotherapy for management of immune effector cell-associated neurotoxicity syndrome (ICANS): A multi-center, real-world analysis of clinical outcomes
Blood · 2025
- Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
Blood Advances · 2023
- Supplementary Figures 1 through 26, Supplementary Tables 1 through 5, and Supplementary Materials and Methods from Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer
2023
- Data from Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer
2023
- Supplementary Figures 1 through 26, Supplementary Tables 1 through 5, and Supplementary Materials and Methods from Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer
2023
- Data from Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer
2023
- Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
Blood · 2022
- Ser‐486/491 phosphorylation and inhibition of AMPKα activity is positively associated with Gleason score, metastasis, and castration‐resistance in prostate cancer: A retrospective clinical study
The Prostate · 2018
- PD32-10 PHOSPHORYLATION OF AMPKα AT SER-485/491 IS ASSOCIATED WITH METASTASIS AND CASTRATION-RESISTANCE IN PROSTATE CANCER: A CLINICAL STUDY
The Journal of Urology · 2016
- Abstract 4963: A distinct AMP-activated protein kinase phosphorylation site is associated with metastasis and castration-resistance in prostate cancer
Cancer Research · 2016
- Blood×3
- The Prostate×2
- Cancer Research×2
- Journal of Clinical Oncology×2
- Transplantation and Cellular Therapy×2
- Asmaa El-Kenawi
Biochemistry, Genetics and Molecular Biology · Indiana University
- Eswar Shankar
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Lei Chen
Biochemistry, Genetics and Molecular Biology · Indiana University
- Faye Zheng
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Deliang Guo
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile